Search

Syndax Pharmaceuticals Inc

Закрыт

СекторЗдравоохранение

16.88 -0.47

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

16.37

Макс.

17.28

Ключевые показатели

By Trading Economics

Доход

-6.7M

-49M

Продажи

7.9M

73M

Прибыль на акцию

-0.55

Рентабельность продаж

-67.817

Сотрудники

298

EBITDA

-5.9M

-37M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+119.22% upside

Дивиденды

By Acuity

Следующий отчет о доходах

2 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-125M

1.6B

Предыдущая цена открытия

17.35

Предыдущая цена закрытия

16.88

Новостные настроения

By Acuity

77%

23%

302 / 340 Рейтинг в Healthcare

Syndax Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

7 окт. 2026 г., 23:20 UTC

Syndax Pharmaceuticals Inc gained modestly in after-market hours, though it remains below its 20-day moving average and near the lower end of its one-month range.

6 окт. 2026 г., 20:07 UTC

Syndax Pharmaceuticals Inc shares fell sharply, hitting a low of over 5% earlier, and remain below the 20-day moving average.

2 окт. 2026 г., 19:15 UTC

Syndax Pharmaceuticals Inc shares fell sharply, facing significant downward pressure and trading notably below its 20-day moving average amid broader biotechnology sector weakness.

1 окт. 2026 г., 20:07 UTC

Social Media

Shares of Syndax Pharmaceuticals fell despite positive analyst ratings from H.C. Wainwright and Jefferies, remaining below the 20-day moving average.

30 сент. 2026 г., 20:07 UTC

Syndax Pharmaceuticals Inc is experiencing gains in Wednesday's trading session, rebounding significantly after an early dip and achieving a notable cumulative return since Tuesday.

29 сент. 2026 г., 23:30 UTC

Syndax Pharmaceuticals Inc is rising in after-market trading, advancing from a low point post-market close and currently near the midpoint of its one-month trading range.

28 сент. 2026 г., 19:16 UTC

News

Syndax Pharmaceuticals Inc. shares fell, remaining below the 20-day moving average despite being rated a "Strong Buy" following FDA approval for Revuforj.

25 сент. 2026 г., 19:46 UTC

News
Social Media

Syndax Pharmaceuticals reaffirms over $2 billion in U.S. peak sales for Revuforj after SAVE trial results show an 88% overall response rate, driving shares higher.

24 сент. 2026 г., 20:12 UTC

Syndax Pharmaceuticals Inc is trading higher in after-market hours, maintaining a steady position since Thursday's close, despite being below its 20-day moving average.

23 сент. 2026 г., 20:07 UTC

Syndax Pharmaceuticals Inc shares fell sharply, reaching their lowest point around midday and remaining below the 20-day moving average after a significant decline from Tuesday's close.

22 сент. 2026 г., 19:45 UTC

Syndax Pharmaceuticals Inc is trading modestly higher, though the price remains below its 20-day moving average and near the lower end of its one-month range.

21 сент. 2026 г., 21:11 UTC

Syndax Pharmaceuticals Inc is advancing in after-market trading, reflecting notable upward movement since Monday's close, despite remaining below its 20-day moving average.

17 сент. 2026 г., 20:07 UTC

Syndax Pharmaceuticals Inc is trading higher, having seen a steady increase, despite being below its 20-day moving average and near the lower end of its one-month range.

16 сент. 2026 г., 20:06 UTC

Macro Event

Syndax Pharmaceuticals Inc shares fell sharply, driven by heightened volatility in the healthcare sector following the Federal Reserve's recent 25 basis point interest rate hike.

15 сент. 2026 г., 20:07 UTC

Syndax Pharmaceuticals Inc shares are lower amid a broader market decline following a sharp drop in the NY Empire State Manufacturing Index for September.

11 сент. 2026 г., 19:36 UTC

News

Syndax Pharmaceuticals is lower today, continuing a downward trend amid heightened market volatility following the August Consumer Price Index release.

10 сент. 2026 г., 20:03 UTC

Syndax Pharmaceuticals Inc shares are lower today, continuing a decline since Wednesday's close, with no specific news identified to explain the movement.

8 сент. 2026 г., 20:07 UTC

News

Syndax Pharmaceuticals is lower today amid broader market weakness and speculation about a Federal Reserve interest rate hike following strong labor data.

2 сент. 2026 г., 20:08 UTC

Syndax Pharmaceuticals Inc shares are higher today, despite earlier pulling back from a session high amid broader market volatility and slower job growth indicators.

1 сент. 2026 г., 20:09 UTC

News

Syndax Pharmaceuticals shares are higher as the company announces participation in two investor conferences to boost visibility for its cancer therapies.

25 авг. 2026 г., 19:26 UTC

Syndax Pharmaceuticals Inc shares are higher today, maintaining gains since Monday. The stock remains above the 20-day moving average amid declining yields.

24 авг. 2026 г., 19:51 UTC

Syndax Pharmaceuticals Inc is trading lower, breaking a trend of higher closes. Broader market sentiment is impacted by concerns over U.S.-Iran relations and oil supply disruptions.

21 авг. 2026 г., 19:21 UTC

Syndax Pharmaceuticals shares are lower today, breaking a trend of higher closes since Thursday. The broader market faces volatility amid rising crude oil prices.

20 авг. 2026 г., 20:02 UTC

Correlated Moves

Syndax trades lower amid decline in SPDR S&P Biotech ETF.

19 авг. 2026 г., 19:27 UTC

Correlated Moves

SNDX higher today, supported by strong biotechnology sector performance.

18 авг. 2026 г., 19:56 UTC

Syndax Pharmaceuticals is trading higher today, despite pulling back from earlier session gains. The stock remains positioned near the lower end of its one-month range.

17 авг. 2026 г., 19:36 UTC

Correlated Moves

Shares higher today as iShares Biotechnology ETF also gains.

14 авг. 2026 г., 19:26 UTC

Syndax Pharmaceuticals Inc shares are trading higher during Friday's session, reflecting positive market sentiment despite broader concerns over a decline in U.S. retail sales.

12 авг. 2026 г., 19:31 UTC

Syndax Pharmaceuticals shares are lower, reversing a recent trend of gains. No specific news was identified to explain the decline.

11 авг. 2026 г., 19:26 UTC

News

SNDX trades lower after JPMorgan cuts price target to $40.00.

Сравнение c конкурентами

Изменение цены

Syndax Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

119.22% рост

Прогноз на 12 месяцев

Средняя 37.333 USD  119.22%

Максимум 57 USD

Минимум 26 USD

Основано на мнении 10 аналитиков Wall Street, спрогнозировавших целевые цены для Syndax Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

10 ratings

10

Покупка

0

Удержание

0

Продажа

Настроения

By Acuity

302 / 340Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства нисходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.